-
2025-06-18
Gensci Showcases Women's Health and Immunology Innovations at BIO 2025Learn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2025-06-17
Gensci Showcases BsADC Pipeline at 4th World ADC Asia SummitLearn More
-
2025-05-30
The FDA has Cleared the IND Application for GenSci128 for TP53 Y220C-Mutated Solid TumorsLearn More
-
2025-05-20
GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone LeaderLearn More
-
2025-03-21
Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.Learn More
-
2024-11-20
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024Learn More
-
2024-11-11
World ADC San Diego 2024: GenSci showcases two innovative pipeline programsLearn More
-
2024-11-07
Welcome to Visit Us at MEDICA 2024Learn More
-
2024-10-25
GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Actionsuccessfully concluded on October 17, 2024
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-08-06
Clinical Trial Commencement of GenSci098 Injection ApprovedPreclinical data indicate GenSci098 has the potential to become a new treatment for Thyroid Eye Disease
Learn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia® in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024Jintrolong® PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More
-
2024-04-11
R&D Progress: NMPA Approves Genakumab to the MarketMajor R&D Progress
Learn More